Navigation Links
The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
Date:1/31/2008

e and easily preventable disease among patients hospitalized for acute medical and surgical illnesses. Deep vein thrombosis (DVT) and pulmonary embolism are common manifestations of VTE and can contribute significantly to morbidity and mortality.

Commenting on the study, Doctor Ander Cohen, Co-chair of the ENDORSE Steering Committee, said "ENDORSE findings are important from national heath care perspectives since they allow estimation of both the patient welfare and economic benefits of fully applying evidence based VTE prophylaxis among hospitalised medical and surgical patients. If we want to improve hospital patient outcomes, we urgently need to implement hospital-wide strategies to identify all surgical and medical patients at risk for VTE and improve the use of appropriate prophylaxis to prevent VTE."

Despite International and local guidelines on VTE management, ENDORSE results illustrate clearly that there is a gap between guidelines evidence and practice in the hospital setting throughout the world. Lack of awareness and uncertainty about the prevalence of patients at risk of VTE are among the major reasons accounting for this gap(2),(3)

As highlighted by Doctor Victor Tapson, Co-chair of the ENDORSE Steering Committee: "ENDORSE clearly shows that VTE is a critical safety issue in hospitalized patients, as the majority of them are at risk for VTE. The increased use of prophylaxis in the surgical setting for which the benefits of prophylaxis have been accepted for many years compared with medical setting for which trials and guidelines are more recent, shows that we have to increase physician awareness on the benefits of prophylaxis particularly in medical patient."

About venous thromboembolism (VTE)

Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (
'/>"/>

SOURCE University of Massachusetts Medical School
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Lancet Publishes Vasogens ACCLAIM Results
2. Vasogens Research Published in European Journal of Neuroscience
3. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
4. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
5. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... August 18, 2014 According ... Market, By Application (Municipal Wastewater Treatment and Industrial ... and Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), ... by MarketsandMarkets, The market for membrane bioreactor systems ... growing at a CAGR of 15.28% between 2014 ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 2011 The 10th annual Evergreen Healthcare Foundation Gala ... and friends of the hospital together at King County,s ... million to kick off a capital campaign that will ... imaging technology.   The "Evening in Paris" ...
... At this year,s American Academy of AntiAging (A4M) conference, ... leading factors in premature aging and disease. AGEs are dangerous ... sugar that attaches to a protein or lipid without the ... completely irreversible—and cause accelerated damage to the tissues and cells. ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... it will release its unaudited financial results for the first ... 13, 2011.  The Company will host a conference call on ... 2011 at 8:00 pm China Standard Time) to review the ...
Cached Biology Technology:Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results 2
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
(Date:8/19/2014)... Science Center at San Antonio and The University of ... of more than $750,000 in grants through the San ... in 2003, SALSI is a model of how a ... center join forces for greater research and graduate education. ... focus on public health issues and diseases of global ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... Two chemicals -- trichloroethylene (TCE) and tetrachloroethylene (PCE) -- ... Base Camp Lejeune from the 1950s to 1985 have ... cancers. A new report from the National Research ... Potential Health Effects, reviews scientific evidence about the potential ...
... humans have evolved to naturally understand things like facial expressions ... found there is an ever-widening gap between what humans can ... successful adults in today,s modern society. Schools have traditionally helped ... the U.S. more may need to be done. "Schools ...
... Australian company Stadvis Pty Ltd have signed a worldwide ... predicts glycemic index (GI) and resistant starch (RS) in ... with an accurate means of testing the functional properties ... is much quicker and more cost-effective than the current ...
Cached Biology News:MU study finds connection between evolution, classroom learning 2CSIRO deal to commercialize 'artificial gut' 2
Immunochemistry 1 & 2...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
Supplemental reagent for annexin V assay....
See product name for description....
Biology Products: